ChAdOx1 nCoV-19 appears to be better tolerated in older adults than in younger adultsand has similar immunogenicity across all age groups after a boost dose. Further assessmentof the efficacy of this vaccine is warranted in all age groups and individuals withcomorbidities.

ChAdOx1 nCoV-19 appears to be better tolerated in older adults than in younger adultsand has similar immunogenicity across all age groups after a boost dose. Further assessmentof the efficacy of this vaccine is warranted in all age groups and individuals withcomorbidities.